Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause

David J Portman, Andrew M Kaunitz, Kazem Kazempour, Hana Mekonnen, Sailaja Bhaskar, Joel Lippman, David J Portman, Andrew M Kaunitz, Kazem Kazempour, Hana Mekonnen, Sailaja Bhaskar, Joel Lippman

Abstract

Objective: Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menopause and had a favorable tolerability profile. The impact of paroxetine 7.5 mg on body weight and sexual function was evaluated in a pooled analysis.

Methods: Postmenopausal women aged 40 years or older who had moderate to severe VMS were randomly assigned to receive paroxetine 7.5 mg or placebo once daily for 12 or 24 weeks. Assessments included changes in body mass index (BMI) and weight, Arizona Sexual Experiences Scale score, Hot Flash-Related Daily Interference Scale sexuality subscore, and adverse events related to weight or sexual dysfunction.

Results: Pooled efficacy and safety populations comprised 1,174 and 1,175 participants, respectively. Baseline values were similar for median weight (∼75 kg), median BMI (∼28 kg/m), and the proportion of women with sexual dysfunction (∼58%). No clinically meaningful or statistically significant changes from baseline in weight or sexual function assessments occurred in the paroxetine 7.5 mg group. Small but statistically significant increases in weight and BMI were observed in the placebo group only on week 4. No significant difference between treatment groups was observed in the proportion of participants who had 7% or higher gain in body weight on week 4, 12, or 24. Rates of adverse events suggestive of sexual dysfunction were low and similar in both treatment groups.

Conclusions: Paroxetine 7.5 mg does not cause weight gain or negative changes in libido when used to treat menopause-associated VMS in postmenopausal women.

Trial registration: ClinicalTrials.gov NCT01101841 NCT01361308.

Figures

FIG. 1
FIG. 1
Study design and timing of evaluations. AE, adverse event; ASEX, Arizona Sexual Experiences Scale; HFRDIS, Hot Flash–Related Daily Interference Scale.
FIG. 2
FIG. 2
Impact of treatment on body mass index (BMI). P values were calculated from rank-transformed analysis of covariance.
FIG. 3
FIG. 3
Impact of treatment on sexual dysfunction. P values were not significant versus placebo for all comparisons. ASEX, Arizona Sexual Experiences Scale.
FIG. 4
FIG. 4
Arizona Sexual Experiences Scale (ASEX) score reductions in hot flash responders and hot flash nonresponders in the paroxetine 7.5 mg group. Responders were defined as women who achieved a 50% or higher reduction in moderate to severe hot flash frequency from baseline. P values are the results of Wilcoxon test.

References

    1. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008; 11: 32- 43.
    1. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013; 16: 235- 239.
    1. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas 2007; 58: 348- 358.
    1. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012; 19: 257- 271.
    1. Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011; 71: 287- 304.
    1. Thacker HL. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. J Womens Health (Larchmt) 2011; 20: 1007- 1016.
    1. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057- 2071.
    1. Rossmanith WG, Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol 2009; 25: 303- 314.
    1. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Coping strategies for antidepressant side effects: an Internet survey. J Affect Disord 2012; 143: 89- 94.
    1. Chervenak JL. Reproductive aging, sexuality and symptoms. Semin Reprod Med 2010; 28: 380- 387.
    1. Hirschberg AL. Sex hormones, appetite and eating behaviour in women. Maturitas 2012; 71: 248- 256.
    1. Data on file (based on research conducted by IMS NPA Market Dynamics), 2012, Noven Pharmaceuticals, Inc.
    1. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289: 2827- 2834.
    1. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919- 6930.
    1. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11: 17- 22.
    1. Joffe H. Low-dose mesylate salt of paroxetine (LDMP) in treatment of vasomotor symptoms (VMS) in menopause. Presented at: Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; San Diego, CA; 2012.
    1. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20: 1027- 1035.
    1. Sussman N, Ginsberg DL. Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psychiatr Ann 1998; 28: 89- 97.
    1. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor– and imipramine-controlled trials. J Clin Psychiatry 2001; 62: 256- 260.
    1. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61: 863- 867.
    1. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26: 25- 40.
    1. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001; 22: 979- 989.
    1. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259- 1272.
    1. Clayton AH. Understanding antidepressant mechanism of action and its effect on efficacy and safety. J Clin Psychiatry 2012; 73: e11.
    1. Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011; 89: 142- 147.
    1. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29: 259- 266.
    1. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011; 155: 772- 785.
    1. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res 2005; 66: 96- 106.
    1. Avis NE, Green R. The perimenopause and sexual functioning. Obstet Gynecol Clin North Am 2011; 38: 587- 594.
    1. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med 2010; 28: 426- 434.
    1. Bachmann GA. Influence of menopause on sexuality. Int J Fertil Menopausal Stud 1995; 40 (suppl 1): 16- 22.
    1. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008; 31: 851- 865.
    1. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 2007; 30: 326- 334.
    1. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357- 366.
    1. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28: 3278- 3283.
    1. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111: 77- 87.
    1. Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012; 119: 527- 538.
    1. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059- 2063.
    1. Loprinzi CL, Sloan JA, Perez PA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578- 1583.
    1. Chiechi LM, Granieri M, Lobascio A, Ferreri R, Loizzi P. Sexuality in the climacterium. Clin Exp Obstet Gynecol 1997; 24: 158- 159.
    1. Dennerstein L, Hayes RD. Confronting the challenges: epidemiological study of female sexual dysfunction and the menopause. J Sex Med 2005; 2 (suppl 3): 118- 132.
    1. Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med 2005; 2: 317- 330.
    1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537- 544.
    1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112: 970- 978.
    1. Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762- 774.
    1. Nicolosi A, Laumann EO, Glasser DB, Moreira ED, Jr, Paik A, Gingell C. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004; 64: 991- 997.
    1. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004; 7: 375- 389.
    1. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1365- 1371.
    1. Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012; 124: 154- 167.
    1. Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol 2011; 14: 367- 375.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi